THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 126 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2021. The put-call ratio across all filers is 0.56 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $39,412,606 | -25.1% | 4,566,930 | -10.1% | 0.00% | 0.0% |
Q2 2023 | $52,590,576 | -5.7% | 5,081,215 | -1.2% | 0.00% | -50.0% |
Q1 2023 | $55,798,047 | -6.7% | 5,142,677 | -3.5% | 0.00% | 0.0% |
Q4 2022 | $59,811,318 | +15.5% | 5,330,777 | +4.4% | 0.00% | 0.0% |
Q3 2022 | $51,789,000 | +13.8% | 5,107,527 | +1.7% | 0.00% | +100.0% |
Q2 2022 | $45,505,000 | -3.4% | 5,022,740 | +1.9% | 0.00% | 0.0% |
Q1 2022 | $47,123,000 | -14.7% | 4,929,140 | -1.5% | 0.00% | 0.0% |
Q4 2021 | $55,276,000 | +46.3% | 5,002,363 | -2.0% | 0.00% | 0.0% |
Q3 2021 | $37,772,000 | -42.5% | 5,104,459 | +12.9% | 0.00% | -50.0% |
Q2 2021 | $65,640,000 | -30.6% | 4,520,707 | -2.4% | 0.00% | -33.3% |
Q1 2021 | $94,583,000 | +18.5% | 4,634,135 | +3.2% | 0.00% | 0.0% |
Q4 2020 | $79,810,000 | +25.0% | 4,491,195 | +4.0% | 0.00% | +50.0% |
Q3 2020 | $63,862,000 | -30.5% | 4,319,434 | -1.3% | 0.00% | -50.0% |
Q2 2020 | $91,894,000 | -54.7% | 4,377,927 | -50.1% | 0.00% | -60.0% |
Q1 2020 | $202,923,000 | +104.7% | 8,780,790 | +129.3% | 0.01% | +150.0% |
Q4 2019 | $99,134,000 | +32.0% | 3,829,079 | -0.7% | 0.00% | +33.3% |
Q3 2019 | $75,129,000 | +20.0% | 3,856,630 | +0.6% | 0.00% | 0.0% |
Q2 2019 | $62,587,000 | -25.7% | 3,832,682 | +3.1% | 0.00% | -25.0% |
Q1 2019 | $84,256,000 | -14.8% | 3,716,673 | -3.8% | 0.00% | -20.0% |
Q4 2018 | $98,857,000 | -21.1% | 3,863,076 | +0.8% | 0.01% | 0.0% |
Q3 2018 | $125,239,000 | +47.2% | 3,833,409 | +2.2% | 0.01% | +25.0% |
Q2 2018 | $85,066,000 | -2.1% | 3,750,789 | +4.7% | 0.00% | 0.0% |
Q1 2018 | $86,888,000 | -16.8% | 3,583,042 | -4.3% | 0.00% | -20.0% |
Q4 2017 | $104,419,000 | -19.9% | 3,743,955 | -1.6% | 0.01% | -28.6% |
Q3 2017 | $130,292,000 | -10.1% | 3,805,227 | +4.6% | 0.01% | -12.5% |
Q2 2017 | $144,972,000 | +12.1% | 3,638,838 | +3.6% | 0.01% | +14.3% |
Q1 2017 | $129,326,000 | +134614.6% | 3,512,445 | +117412.4% | 0.01% | – |
Q4 2016 | $96,000 | -9.4% | 2,989 | +2.0% | 0.00% | – |
Q3 2016 | $106,000 | +21.8% | 2,930 | -23.3% | 0.00% | – |
Q2 2016 | $87,000 | +163.6% | 3,821 | +114.8% | 0.00% | – |
Q1 2016 | $33,000 | +200.0% | 1,779 | +155.6% | 0.00% | – |
Q4 2015 | $11,000 | +37.5% | 696 | 0.0% | 0.00% | – |
Q3 2015 | $8,000 | -11.1% | 696 | 0.0% | 0.00% | – |
Q2 2015 | $9,000 | -25.0% | 696 | 0.0% | 0.00% | – |
Q1 2015 | $12,000 | +20.0% | 696 | 0.0% | 0.00% | – |
Q4 2014 | $10,000 | -37.5% | 696 | 0.0% | 0.00% | – |
Q3 2014 | $16,000 | -30.4% | 696 | 0.0% | 0.00% | – |
Q2 2014 | $23,000 | – | 696 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
King Wealth Management Group | 22,500 | $583,000 | 0.15% |
Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |